₩ăřņîñĞ Posted August 10, 2016 Posted August 10, 2016 Misoblast said that the experimental treatment developed by stem cells, led to a significant improvement in symptoms and arthritis disease activity in patients who stop vital medicines used widely in their help, according to data from the intermediate phase of the experiment. The company said that the product relies on mesenchymal stem cells and carries the name NBC-300-IE., seemed significantly as did not show any serious side effects or problems related to infusion therapy in the study phase, which lasted 12 weeks and included 48 patients. Among patients who had been treated with medication at least one dynamic, 55 percent who received a dose of 2 million cell per kilogram of weight, witnessed a decline in arthritis symptoms 20 percent. It came as compared to 33 percent in the group taking a placebo. 36 percent saw reduced symptoms by seventy percent after a dose of misoblast therapy compared with no one from the placebo group. The company said that the stem cell therapy also led to an improvement in measures of bodily functions and disease activity in General compared to placebo. Alan gibevoski is a medical doctor specializing in rheumatology at the hospital for special surgery in New York, "safety and effectiveness results of this study are very encouraging and suggest that stem cell therapy developed by misoblast can meet unmet medical needs".
Recommended Posts